FDA approves generic postop inflammation drug

The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).

 

Amityville, NY-The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).

The drug-which is the generic form of ISTA Pharmaceuticals’ Bromday ophthalmic solution, 0.09%-is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Hi-Tech plans to launch the product immediately.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.